Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 314 results
Filters: First Letter Of Last Name is G  [Clear All Filters]
Found 314 results.

2018

Taiwo BO, Zheng L, Stefanescu A, et al. "ACTG A5353: A Pilot Study of Dolutegravir Plus Lamivudine for Initial Treatment of Human Immunodeficiency Virus-1 (HIV-1)-infected Participants With HIV-1 RNA <500000 Copies/mL." Clin. Infect. Dis.. 2018;66(11):1689-1697.
Presti RM, Handley SA, Droit L, et al. "Alterations in the oral microbiome in HIV-infected participants after antiretroviral therapy administration are influenced by immune status." AIDS. 2018;32(10):1279-1287.
Cespedes MS, Kang M, Kojic EMilunka, et al. "Anogenital human papillomavirus virus DNA and sustained response to the quadrivalent HPV vaccine in women living with HIV-1." Papillomavirus Res. 2018;6:15-21.
Gandhi M, Ofokotun I, Bacchetti P, et al. "Antiretroviral concentrations in hair strongly predict virologic response in a large HIV treatment-naive clinical trial." Clin. Infect. Dis.. 2018.
Hosseinipour MC, Kang M, Krown SE, et al. "As-Needed versus Immediate Etoposide Chemotherapy in Combination with Antiretroviral Therapy for Mild or Moderate AIDS-associated Kaposi Sarcoma in Resource-Limited Settings: A5264/AMC-067 Randomized Clinical Trial." Clin. Infect. Dis.. 2018.
Haas DW, Bradford Y, Verma A, et al. "Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events." Pharmacogenet. Genomics. 2018;28(7):179-187.
Namazi G, Fajnzylber JM, Aga E, et al. "The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical Studies." J. Infect. Dis.. 2018;218(12):1954-1963.
Gandhi M, Gandhi RT, Stefanescu A, et al. "Cumulative Antiretroviral Exposure Measured in Hair Is Not Associated With Measures of HIV Persistence or Inflammation Among Individuals on Suppressive ART." J. Infect. Dis.. 2018;218(2):234-238.
Shivakoti R, Ewald ER, Gupte N, et al. "Effect of baseline micronutrient and inflammation status on CD4 recovery post-cART initiation in the multinational PEARLS trial." Clin Nutr. 2018.
Strongin Z, Sharaf R, D VanBelzen J, et al. "Effect of Short-Term Antiretroviral Therapy Interruption on Levels of Integrated HIV DNA." J. Virol.. 2018;92(12).
Stockdale AJ, Saunders MJ, Boyd MA, et al. "Effectiveness of Protease Inhibitor/Nucleos(t)ide Reverse Transcriptase Inhibitor-Based Second-line Antiretroviral Therapy for the Treatment of Human Immunodeficiency Virus Type 1 Infection in Sub-Saharan Africa: A Systematic Review and Meta-analysis." Clin. Infect. Dis.. 2018;66(12):1846-1857.
Moro RN, Scott NA, Vernon A, et al. "Exposure to Latent Tuberculosis Treatment during Pregnancy. The PREVENT TB and the iAdhere Trials." Ann Am Thorac Soc. 2018;15(5):570-580.
Figueroa DB, Madeen EP, Tillotson J, et al. "Genetic Variation of the Kinases That Phosphorylate Tenofovir and Emtricitabine in Peripheral Blood Mononuclear Cells." AIDS Res. Hum. Retroviruses. 2018;34(5):421-429.
Gianella S, Marconi VC, Berzins B, et al. "Genital HIV-1 Shedding With Dolutegravir (DTG) Plus Lamivudine (3TC) Dual Therapy." J. Acquir. Immune Defic. Syndr.. 2018;79(5):e112-e114.
Kallianpur AR, Gerschenson M, Hulgan T, et al. "Hemochromatosis (HFE) Gene Variants Are Associated with Increased Mitochondrial DNA Levels During HIV-1 Infection and Antiretroviral Therapy." AIDS Res. Hum. Retroviruses. 2018;34(11):942-949.
Ngongondo MN, Miyahara S, Hughes MD, et al. "Hepatotoxicity During Isoniazid Preventive Therapy and Antiretroviral Therapy in People Living With HIV With Severe Immunosuppression: A Secondary Analysis of a Multi-Country Open-Label Randomized Controlled Clinical Trial." J. Acquir. Immune Defic. Syndr.. 2018;78(1):54-61.
Cranston RD, Cespedes MS, Paczuski P, et al. "High Baseline Anal Human Papillomavirus and Abnormal Anal Cytology in a Phase 3 Trial of the Quadrivalent Human Papillomavirus Vaccine in Human Immunodeficiency Virus-Infected Individuals Older Than 26 Years: ACTG 5298." Sex Transm Dis. 2018;45(4):266-271.
Opollo VS, Wu X, Hughes MD, et al. "HIV testing uptake among the household contacts of multidrug-resistant tuberculosis index cases in eight countries." Int. J. Tuberc. Lung Dis.. 2018;22(12):1443-1449.
Sharaf R, Lee GQ, Sun X, et al. "HIV-1 proviral landscapes distinguish posttreatment controllers from noncontrollers." J. Clin. Invest.. 2018;128(9):4074-4085.
Bares SH, Smeaton LM, Xu A, Godfrey C, McComsey GA. "HIV-Infected Women Gain More Weight than HIV-Infected Men Following the Initiation of Antiretroviral Therapy." J Womens Health (Larchmt). 2018;27(9):1162-1169.
Shivakoti R, Gupte N, Tripathy S, et al. "Inflammation and micronutrient biomarkers predict clinical HIV treatment failure and incident active TB in HIV-infected adults: a case-control study." BMC Med. 2018;16(1):161.
Martin MP, Naranbhai V, Shea PR, et al. "Killer cell immunoglobulin-like receptor 3DL1 variation modifies HLA-B*57 protection against HIV-1." J. Clin. Invest.. 2018;128(5):1903-1912.
Lidofsky A, Holmes JA, Feeney ER, et al. "Macrophage Activation Marker Soluble CD163 Is a Dynamic Marker of Liver Fibrogenesis in Human Immunodeficiency Virus/Hepatitis C Virus Coinfection." J. Infect. Dis.. 2018;218(9):1394-1403.
Kapadia SN, Wu C, Mayer KH, et al. "No change in health-related quality of life for at-risk U.S. women and men starting HIV pre-exposure prophylaxis (PrEP): Findings from HPTN 069/ACTG A5305." PLoS ONE. 2018;13(12):e0206577.
Wilkin TJ, Chen H, Cespedes MS, et al. "A Randomized, Placebo-Controlled Trial of the Quadrivalent Human Papillomavirus Vaccine in Human Immunodeficiency Virus-Infected Adults Aged 27 Years or Older: AIDS Clinical Trials Group Protocol A5298." Clin. Infect. Dis.. 2018;67(9):1339-1346.
Swindells S, Gupta A, Kim S, et al. "Resource utilization for multidrug-resistant tuberculosis household contact investigations (A5300/I2003)." Int. J. Tuberc. Lung Dis.. 2018;22(9):1016-1022.
Benson CA, Andersen JW, Macatangay BJC, et al. "Safety and Immunogenicity of Zoster Vaccine Live in Human Immunodeficiency Virus-Infected Adults With CD4+ Cell Counts >200 Cells/mL Virologically Suppressed on Antiretroviral Therapy." Clin. Infect. Dis.. 2018;67(11):1712-1719.
Hoenigl M, Moser C, Funderburg N, et al. "Soluble Urokinase Plasminogen Activator Receptor (suPAR) is predictive of Non-AIDS Events during Antiretroviral Therapy-mediated Viral Suppression." Clin. Infect. Dis.. 2018.
Kalayjian RC, Albert JM, Cremers S, et al. "Women have enhanced bone loss associated with phosphaturia and CD4+ cell restoration during initial antiretroviral therapy." AIDS. 2018;32(17):2517-2524.

Pages